Clinical trial · Observational
Value of PET-CT in Radiation Treatment Planning for Patients With Esophageal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The RESPECT study is intended to prospectively assess the impact of PET/CT on the delineation of target volumes and to estimate the proportion of recurrences that could possibly be prevented by the use of PET/CT-based target volume, instead of CT-based. Patients will recieve radiotherapy using CT-based planning, but a PET/CT-based treatment plan will also be made. CT-based and PET/CT-based target volumes will be compared after treatment has been completed. If a locoregional recurrence takes place, the localisation will be compared to the CT-based and PET/CT based clinical target volumes (CTVs). If the local recurrence is located outside the CT-CTV but inside the PET/CT-CTV, the recurrence could possibly have been prevented with PET/CT-based radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Radiotherapy for esophageal cancer
- description
- Patients with histology proven esophageal cancer who are planned for high dose radiotherapy with or without chemotherapy with or without surgery.
Primary outcomes (1)
- measure
- Preventable locoregional recurrence by the use of PET/CT-based treatment planning, instead of CT-based
- timeFrame
- 18 months
- description
- Proportion of patients with a locoregional recurrence, observed at 6, 12 or 18 months after treatment, can the recurrence be considered as possibly preventable if PET/CT-based treatment planning was used instead of CT-based treatment planning alone (located outside the CT-based CTV, but inside the PET/CT-based CTV)
Secondary outcomes (4)
- measure
- Differences in GTV, CTV and PTV for CT-based and PET/CT-based treatment planning
- timeFrame
- 6 months
- description
- Differences in GTV (gross target volume), CTV and PTV (planning target volume) for CT-based and PET/CT-based treatment planning
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:- Histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus or GEJ * Locally curable disease without distant metastases (M1b is excluded) (TNM clinical classification UICC 7th edition) * Planned for high dose radiotherapy with or without chemotherapy with or without surgery * Age ≥ 18 years; * WHO performance status 0-2 * informed consent must be given according to ICH/EU GCP, and national/local regulations Exclusion Criteria:- previous or concurrent malignancies (except basal cell carcinoma of the skin or in situ carcinoma of the cervix or superficial bladder cancer (pTa)) in the past five years * Previous treatment * Evidence of serious active infections * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
References
Publications (2)
- BACKGROUNDMuijs CT, Beukema JC, Pruim J, Mul VE, Groen H, Plukker JT, Langendijk JA. A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiother Oncol. 2010 Nov;97(2):165-71. doi: 10.1016/j.radonc.2010.04.024. Epub 2010 Jun 10. PMID 20541273
- RESULTMuijs CT, Pruim J, Beukema JC, Berveling MJ, Plukker JT, Langendijk JA. Oesophageal tumour progression between the diagnostic (1)(8)F-FDG-PET and the (1)(8)F-FDG-PET for radiotherapy treatment planning. Radiother Oncol. 2013 Mar;106(3):283-7. doi: 10.1016/j.radonc.2012.10.015. Epub 2012 Nov 27. PMID 23199654